Llwytho...
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?
Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in luminal breast cancer (BC). Despite the efficacy of endocrine agents, many patients with luminal BC do not respond to endocrine therapy and many others develop endocrine resistance over time, due to the activ...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Breast Care (Basel) |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
S. Karger GmbH
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5704698/ https://ncbi.nlm.nih.gov/pubmed/29234247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481657 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|